Sema4 Holdings Corp. (NASDAQ:SMFR) CFO Sells $48,006.90 in Stock

Sema4 Holdings Corp. (NASDAQ:SMFRGet Rating) CFO Isaac Ro sold 19,515 shares of Sema4 stock in a transaction dated Tuesday, May 10th. The stock was sold at an average price of $2.46, for a total value of $48,006.90. Following the completion of the transaction, the chief financial officer now directly owns 201,786 shares in the company, valued at approximately $496,393.56. The sale was disclosed in a document filed with the SEC, which is available at this link.

Isaac Ro also recently made the following trade(s):

  • On Wednesday, April 6th, Isaac Ro sold 1,284 shares of Sema4 stock. The stock was sold at an average price of $2.91, for a total value of $3,736.44.

Shares of Sema4 stock traded up $0.16 during trading on Thursday, hitting $1.72. 3,860,145 shares of the stock traded hands, compared to its average volume of 1,730,884. The company has a quick ratio of 4.44, a current ratio of 4.77 and a debt-to-equity ratio of 0.08. Sema4 Holdings Corp. has a twelve month low of $1.49 and a twelve month high of $15.21. The company has a fifty day moving average price of $2.64 and a two-hundred day moving average price of $4.24.

Sema4 (NASDAQ:SMFRGet Rating) last announced its quarterly earnings results on Monday, March 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.05. The firm had revenue of $57.80 million for the quarter, compared to analyst estimates of $50.90 million. On average, equities research analysts expect that Sema4 Holdings Corp. will post -0.8 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in SMFR. Deerfield Management Company L.P. Series C acquired a new stake in shares of Sema4 during the 3rd quarter valued at about $105,110,000. SB Management Ltd acquired a new stake in Sema4 in the 3rd quarter worth approximately $68,473,000. Casdin Capital LLC acquired a new stake in Sema4 in the 3rd quarter worth approximately $37,950,000. Morgan Stanley acquired a new stake in Sema4 in the 3rd quarter worth approximately $27,688,000. Finally, Decheng Capital Management III Cayman LLC acquired a new stake in Sema4 in the 1st quarter worth approximately $10,496,000.

A number of equities research analysts have commented on the company. BTIG Research restated a “buy” rating and set a $8.00 price objective on shares of Sema4 in a research report on Friday, January 21st. Zacks Investment Research lowered Sema4 from a “hold” rating to a “sell” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Sema4 has a consensus rating of “Buy” and an average price target of $11.50.

About Sema4 (Get Rating)

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services.

See Also

Insider Buying and Selling by Quarter for Sema4 (NASDAQ:SMFR)

Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with MarketBeat.com's FREE daily email newsletter.